fda glp-1 compounding enforcement november 2025 Novo Nordisk expands legal action to protect US patients from unsafe, non- FDA-approved compounded "semaglutide" Diabetes advocacy group discourages use

a liquid alternative to capsules or tablets

Beyond increasing appetite-suppressing hormones and peptides, GLP1-RAs act on the mesolimbic reward pathway

NAD+ Therapy Cellular energy and anti-aging support through NAD+ replenishment available as injection, nasal spray, or cream

Others rely more heavily on animal, in vitro, or older endocrine studies

Clinical evidence suggests combination therapy may offer complementary benefits for glucose control and weight management, with metformin addressing insulin resistance through one pathway while GLP-1 agents work through appetite and glucose regulation

First, it was a single-center study with a relatively small sample size, which may limit the generalizability of our findings